Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | Director | July 07, 2026 | July 09, 2026 |
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | January 23, 2025 | January 27, 2025 |
| Medicine Man Technologies, Inc.SHWZ · Entity 71964 | Incorrect Filing | October 28, 2022 | December 02, 2022 |
| TITAN PHARMACEUTICALS INCTTNP · Entity 74432 | Director · Executive Chairman | January 05, 2022 | January 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.29 · Expires 2036-07-06 | Direct | 6,800 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 6,800 · Balance 6,800 F1: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on July 7, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on July 7, 2027.
GALECTIN THERAPEUTICS INC
Report date January 23, 2025 · Filed January 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2035-01-23 | Direct | 60,000 |
Reported balance
After 2025-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-23 · Grant · Acquired 60,000 · Balance 60,000 F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2: The options vest 100% on December 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest 100% on December 31, 2025.
Medicine Man Technologies, Inc.
Report date October 28, 2022 · Filed December 02, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Cumulative Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2022-10-28 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance Not disclosed F1: Due to a clerical error, this Form 3 was initially filed on November 7, 2022 using an incorrect CIK code. The filing was intended to relate to Marc R Rubin. The Reporting Person does not beneficially own any securities in Medicine Man Technologies, Inc. |
| 13% Senior Convertible Note Due 2026SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2022-10-28 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F1: Due to a clerical error, this Form 3 was initially filed on November 7, 2022 using an incorrect CIK code. The filing was intended to relate to Marc R Rubin. The Reporting Person does not beneficially own any securities in Medicine Man Technologies, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Due to a clerical error, this Form 3 was initially filed on November 7, 2022 using an incorrect CIK code. The filing was intended to relate to Marc R Rubin. The Reporting Person does not beneficially own any securities in Medicine Man Technologies, Inc.
TITAN PHARMACEUTICALS INC
Report date January 05, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2032-01-05 | Direct | 65,000 |
Reported balance
After 2022-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-05 · Grant · Acquired 65,000 · Balance 65,000 F1: The options vest as to 32,500 shares on July 5, 2022 with the balance to vest in equal monthly installments over the 18 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as to 32,500 shares on July 5, 2022 with the balance to vest in equal monthly installments over the 18 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2016 Filed Dec 19, 2016 21:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 51,500 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001179022-16-000130 · edgar.xml · derivative · entry 1 Rubin Marc · CIK 0001412377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,500 Underlying: Common stock · 51,500 shares Expires 2026-12-15 F1 · derivative.exercise_date: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.